| Identification | Back Directory | [Name]
(3S,5S)-Atorvastatin (sodium salt) | [CAS]
1428118-38-0 | [Synonyms]
Atorvastatin EP Impurity E Sodium Salt
Atorvastatin impurity 32/(3S,5S)-Atorvastatin Sodium Salt/Atorvastatin EP Impurity E Sodium Salt/(3S,5S)-Atorvastatin Calcium Salt/((3S,5S)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- (phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate) Sodium Sal
Atorvastatin impurity 32/(3S,5S)-Atorvastatin Sodium Salt/Atorvastatin EP Impurity E Sodium Salt/(3S,5S)-Atorvastatin Calcium Salt/((3S,5S)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- (phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate) Sodium Salt | [Molecular Formula]
C66H67CaF2N4NaO10 | [MDL Number]
MFCD18251281 | [MOL File]
1428118-38-0.mol | [Molecular Weight]
1177.32 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
≤0.5mg/ml in ethanol;15mg/ml in DMSO;25mg/ml in dimethyl formamide | [form ]
crystalline solid | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Uses]
(3S,5S)-Atorvastatin Sodium Salt (Atorvastatin EP Impurity E) is a selective, competitive HMG-CoA reductase inhibitor. The only drug in its class specfically indicated for lowering both elevated LDL-cholesterol and triglycerides in patients with hypercholesterolemia. | [Biological Activity]
atorvastatin exists in four optical forms. the (3r, 5r)-atorvastatin enantiomer displays the greatest activity against hmg-coa reductase. (3s,5s)-atorvastatin is an enantiomer of atorvastatin with little or no inhibitory activity against hmg-coa reductase [1]. atorvastatin is a synthetic hmg-coa reductase inhibitor implicated in lowering plasma cholesterol levels by inhibiting endogenous cholesterol synthesis. atorvastatin also reduces triglyceride levels through an as yet unproven mechanism [2]. in various trials in patients with hypercholesterolaemia, atorvastatin produced greater reductions in total cholesterol, apolipoprotein b, ldl-cholesterol and triglyceride levels. in patients with primary hypercholesterolaemia, atorvastatin in combination with colestipol produced significant reductions in ldl-cholesterol levels and smaller reductions in triglyceride levels than atorvastatin monotherapy [2]. | [References]
[1] kocarek t a, dahn m s, cai h, et al. regulation of cyp2b6 and cyp3a expression by hydroxymethylglutaryl coenzyme a inhibitors in primary cultured human hepatocytes[j]. drug metabolism and disposition, 2002, 30(12): 1400-1405.
[2] lea a p, mctavish d. atorvastatin[j]. drugs, 1997, 53(5): 828-847. |
|
| Company Name: |
Pharma Affiliates
|
| Tel: |
172-5066494 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList694812/0_EN.htm |
|